Advertisement

Renal Cell Carcinoma: Opportunity for Bristol-Myers Squibb

Renal Cell Carcinoma: Opportunity for Bristol-Myers Squibb

In Bristol-Myers Squibb’s (BMY) third-quarter earnings conference call, the company estimated the contribution of RCC (renal cell carcinoma) indication to Opdivo’s US and ex-US market revenues to be close to 20% each.